TIRAT CARMEL, Israel, June 19, 2012 (GLOBE NEWSWIRE) -- D. Medical Industries Ltd. (Nasdaq:DMED) (TASE:DMED) ("D. Medical" or the "Company"), announced today that it is negotiating a potential acquisition transaction with an unaffiliated third party in the business of medical devices for diabetes (the "Target"), pursuant to which the Company (or any of its wholly owned subsidiaries) will purchase 100% of the issued and outstanding share capital of the Target from its current shareholders, in exchange for a combination of cash and shares of the Company and/or its subsidiary.
The Company noted that there can be no assurance that the negotiations will result in a transaction that the Company's board of directors determines is in the best interests of the Company or its shareholders. Further, there is no assurance concerning the form, structure, timing or terms and conditions of any such transaction. The Company may not disclose developments with respect to its negotiations with the Target and its shareholders, unless and until the Company's board of directors has approved a specific transaction.
About D. Medical
D. Medical is a medical device company that holds through its subsidiaries a portfolio of products and intellectual property in the area of insulin and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. For more information, please visit http://www.dmedicalindustries.com (corporate) and http://www.springnow.com (healthcare professionals, patients and care givers).
This press release contains forward-looking statements (as defined by the Israeli Securities Law, 1968, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. These statements include, forecasts, goals, uncertainties and assumptions and relate, inter alia, to D. Medical's negotiations regarding a potential acquisition transaction, and the structure or the feasibility of any potential transaction that may arise in connection with such negotiations. The forward-looking statements are based on D. Medical's current expectations and beliefs which are based on, among other things, its analysis of publicly available information and market research reports. All forward-looking statements are subject to certain risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them transpire or occur, what impact it will have on D. Medical's results of operations or financial condition. D. Medical does not undertake to update any forward-looking statements.
CONTACT: Company Contact: Amir Loberman Chief Financial Officer D. Medical Industries LTD T: +972-73-2507135 email@example.com North American Investor Contact: Stephen Kilmer Kilmer Lucas Inc. T: 212-618-6347 firstname.lastname@example.org